Corium International Inc. (NASDAQ:CORI) – Equities researchers at Jefferies Group issued their Q3 2017 EPS estimates for shares of Corium International in a note issued to investors on Wednesday. Jefferies Group analyst D. Steinberg forecasts that the brokerage will earn ($0.43) per share for the quarter. Jefferies Group also issued estimates for Corium International’s Q4 2017 earnings at ($0.46) EPS.

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Several other brokerages also recently weighed in on CORI. FBR & Co set a $18.00 target price on Corium International and gave the stock a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research downgraded Corium International from a “hold” rating to a “sell” rating in a research report on Tuesday, October 11th. Leerink Swann set a $16.00 price target on Corium International and gave the stock a “buy” rating in a research note on Tuesday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Corium International in a research note on Monday, September 26th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Corium International presently has a consensus rating of “Buy” and an average target price of $12.25.

Shares of Corium International (NASDAQ:CORI) remained flat at $4.70 on Thursday. 128,830 shares of the company traded hands. Corium International has a 1-year low of $3.14 and a 1-year high of $9.93. The company’s 50-day moving average price is $5.04 and its 200 day moving average price is $4.71. The firm’s market cap is $104.37 million.

A number of hedge funds have recently made changes to their positions in CORI. RTW Investments LLC boosted its stake in shares of Corium International by 22.6% in the third quarter. RTW Investments LLC now owns 1,045,747 shares of the biopharmaceutical company’s stock valued at $5,888,000 after buying an additional 192,786 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Corium International during the second quarter valued at about $152,000. Finally, Opaleye Management Inc. boosted its stake in shares of Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 88.35% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2016/11/24/corium-international-inc-cori-forecasted-to-earn-q3-2017-earnings-of-0-43-per-share.html.

Corium International Company Profile

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

5 Day Chart for NASDAQ:CORI

Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.